FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2008698478> ?p ?o ?g. }

• W2008698478 endingPage "753" @default.
• W2008698478 startingPage "744" @default.
• W2008698478 abstract "Interleukin‐1 ( IL ‐1) inhibitors potentially have a role as antiinflammatory agents in refractory gout or for patients who are unable to tolerate conventional therapy, such as nonsteroidal antiinflammatory drugs ( NSAID s), colchicine, or glucocorticoids, for acute attacks. Additionally, IL ‐1 inhibitors may also help patients with polyarticular and tophaceous gout by making them less vulnerable to breakthrough attacks during initiation of chronic urate‐lowering treatment, the mainstay of gout therapy. Because evidence highlights the role of proinflammatory cytokine IL ‐1 in the inflammation process during an acute gouty attack, IL ‐1 inhibitors are used to modulate the pathogenesis of a variety of autoinflammatory diseases, providing support for its potential role in the inflammatory process of gout. After NSAID s, colchicine, and steroids, IL ‐1 inhibitors are beneficial as fourth‐line therapy for acute gout attacks due to their high cost and limited clinical experience. The IL ‐1 inhibitors used in gout are anakinra, canakinumab, and rilonacept. Based on published evidence, anakinra has limited support in the form of anecdotal case reports to justify its use for treating gout. Canakinumab's toxic profile in clinical trials precludes its use in treating patients for gout, and rilonacept shows promise with a few well‐designed studies to support its use in gout patients initiating urate‐lowering treatment. When combined with current traditional therapies, these newer agents present clinicians and patients with more potential treatment options in the difficult‐to‐treat gout population." @default.
• W2008698478 created "2016-06-24" @default.
• W2008698478 creator A5026966136 @default.
• W2008698478 creator A5044630615 @default.
• W2008698478 creator A5060740497 @default.
• W2008698478 creator A5083594955 @default.
• W2008698478 creator A5087702198 @default.
• W2008698478 date "2013-04-03" @default.
• W2008698478 modified "2023-10-18" @default.
• W2008698478 title "Role of Interleukin-1 Inhibitors in the Management of Gout" @default.
• W2008698478 cites W1701460655 @default.
• W2008698478 cites W1751586879 @default.
• W2008698478 cites W1977356210 @default.
• W2008698478 cites W1982703566 @default.
• W2008698478 cites W1996930866 @default.
• W2008698478 cites W1999388739 @default.
• W2008698478 cites W2009800174 @default.
• W2008698478 cites W2023429621 @default.
• W2008698478 cites W2029616970 @default.
• W2008698478 cites W2030472946 @default.
• W2008698478 cites W2034938236 @default.
• W2008698478 cites W2044334793 @default.
• W2008698478 cites W2046656162 @default.
• W2008698478 cites W2054682176 @default.
• W2008698478 cites W2067732852 @default.
• W2008698478 cites W2072756541 @default.
• W2008698478 cites W2075505106 @default.
• W2008698478 cites W2077441618 @default.
• W2008698478 cites W2084187644 @default.
• W2008698478 cites W2092339860 @default.
• W2008698478 cites W2099748786 @default.
• W2008698478 cites W2100379211 @default.
• W2008698478 cites W2103723965 @default.
• W2008698478 cites W2109581831 @default.
• W2008698478 cites W2114365596 @default.
• W2008698478 cites W2122152368 @default.
• W2008698478 cites W2134049088 @default.
• W2008698478 cites W2137091038 @default.
• W2008698478 cites W2138587308 @default.
• W2008698478 cites W2149374693 @default.
• W2008698478 cites W2150169647 @default.
• W2008698478 cites W2151809600 @default.
• W2008698478 cites W2156895888 @default.
• W2008698478 cites W2159499116 @default.
• W2008698478 cites W2161000675 @default.
• W2008698478 cites W2335116089 @default.
• W2008698478 doi "https://doi.org/10.1002/phar.1265" @default.
• W2008698478 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23553601" @default.
• W2008698478 hasPublicationYear "2013" @default.
• W2008698478 type Work @default.
• W2008698478 sameAs 2008698478 @default.
• W2008698478 citedByCount "23" @default.
• W2008698478 countsByYear W20086984782013 @default.
• W2008698478 countsByYear W20086984782014 @default.
• W2008698478 countsByYear W20086984782015 @default.
• W2008698478 countsByYear W20086984782016 @default.
• W2008698478 countsByYear W20086984782017 @default.
• W2008698478 countsByYear W20086984782018 @default.
• W2008698478 countsByYear W20086984782021 @default.
• W2008698478 countsByYear W20086984782022 @default.
• W2008698478 countsByYear W20086984782023 @default.
• W2008698478 crossrefType "journal-article" @default.
• W2008698478 hasAuthorship W2008698478A5026966136 @default.
• W2008698478 hasAuthorship W2008698478A5044630615 @default.
• W2008698478 hasAuthorship W2008698478A5060740497 @default.
• W2008698478 hasAuthorship W2008698478A5083594955 @default.
• W2008698478 hasAuthorship W2008698478A5087702198 @default.
• W2008698478 hasConcept C126322002 @default.
• W2008698478 hasConcept C164027704 @default.
• W2008698478 hasConcept C177713679 @default.
• W2008698478 hasConcept C2776636253 @default.
• W2008698478 hasConcept C2776914184 @default.
• W2008698478 hasConcept C2779134260 @default.
• W2008698478 hasConcept C2779721657 @default.
• W2008698478 hasConcept C2779725882 @default.
• W2008698478 hasConcept C2779881121 @default.
• W2008698478 hasConcept C2780402116 @default.
• W2008698478 hasConcept C2780932893 @default.
• W2008698478 hasConcept C2781228260 @default.
• W2008698478 hasConcept C2908647359 @default.
• W2008698478 hasConcept C71924100 @default.
• W2008698478 hasConcept C99454951 @default.
• W2008698478 hasConceptScore W2008698478C126322002 @default.
• W2008698478 hasConceptScore W2008698478C164027704 @default.
• W2008698478 hasConceptScore W2008698478C177713679 @default.
• W2008698478 hasConceptScore W2008698478C2776636253 @default.
• W2008698478 hasConceptScore W2008698478C2776914184 @default.
• W2008698478 hasConceptScore W2008698478C2779134260 @default.
• W2008698478 hasConceptScore W2008698478C2779721657 @default.
• W2008698478 hasConceptScore W2008698478C2779725882 @default.
• W2008698478 hasConceptScore W2008698478C2779881121 @default.
• W2008698478 hasConceptScore W2008698478C2780402116 @default.
• W2008698478 hasConceptScore W2008698478C2780932893 @default.
• W2008698478 hasConceptScore W2008698478C2781228260 @default.
• W2008698478 hasConceptScore W2008698478C2908647359 @default.
• W2008698478 hasConceptScore W2008698478C71924100 @default.
• W2008698478 hasConceptScore W2008698478C99454951 @default.
• W2008698478 hasIssue "7" @default.

• next